Skip to main content
EJNMMI Research
Figure 2 | EJNMMI Research

Figure 2

From: Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Figure 2

Summary of the dose-ranging study (1.0 to 5.0 mg/kg) with [18F] FDG-PET imaging. (a) Anti-tumor activities of the RO4987655 in NCI-H2122 tumor xenografted mice on days 0, 1 and 3 of the treatment. (b) Dose-and time-dependent FDG tumor uptake from day 0 (baseline) to day 3 of the treatment. Analysis of SUVmax values between dose groups on day 1 (c) and day 3 (d) of the treatment.

Back to article page